Edward L. Erickson

Biography

 Edward L. Erickson has extensive domestic and international managerial experience in diagnostics, therapeutics, and life science research products having served as president, CEO or a director of over a dozen private and public companies in these industries. Mr. Erickson is currently non-executive chairman of MDxHealth, S.A. {EuroNext:MDXH}, a publicly-traded molecular diagnostics company, serves as a director of Saladax Biomedical, Inc. and is a director of CertiRx Corporation. His top management experience includes service as president and CEO of Saladax, a diagnostics company specializing in companion diagnostic and therapeutic dose management assays. Prior to Saladax, he served as interim president and CEO of BioNanomatrix, Inc. (now BioNano Genomics), a privately held genomics company developing and commercializing proprietary DNA analysis systems. Previously, he was Chairman, President and CEO of Cellatope Corporation, a private company developing diagnostic products in the field of autoimmune diseases. Prior to this, he served in top leadership roles, including president, CEO and/or chairman, of three venture-capital backed medical products companies, Cholestech (diagnostics), DepoTech (pharmaceuticals/drug delivery) and Immunicon (diagnostics), which successfully completed initial public offerings under his leadership. Earlier in his career, he held senior executive positions at The Ares-Serono Group (acquired by Merck, KGaA) and Amersham International (acquired by GE). His board experience includes service as an independent director and his board committee experience includes chairmanship and/or membership in the Audit, Compensation, Nominating & Governance and Transaction (M&A) committees of both public and private corporations.  Early in his career he worked in the fields of information technology, energy and natural resources, and defense systems. Mr. Erickson holds an MBA with high distinction from the Harvard Graduate School of Business Administration, where he was elected a Baker Scholar and was awarded the Loeb Rhoades Fellowship in Finance. He received a B.S. in Mathematics with a minor in Physics from the Illinois Institute of Technology, where he also completed his M.S. in Mathematics. He did military service as an officer in the U.S. Navy’s nuclear submarine force, including duty aboard the USS Nautilus (SSN-571), the world’s first nuclear submarine.

Research Interest

 Oncology